Literature DB >> 3652281

Treatment of lower urinary tract infections in children: single dose fosfomycin trometamol versus pipemidic acid.

P Careddu1, M Borzani, L Scotti, F Varotto, L Garlaschi, P Fontana.   

Abstract

Fifty-one children suffering from symptomatic and asymptomatic recurrent urinary tract infections were treated at random in a comparative study. A single dose of 2 g fosfomycin trometamol was administered to 24 children (2 males and 22 females, mean age 6.7 +/- 3.3 yr) and two 200 mg doses of pipemidic acid (400 mg in children weighing more than 25 kg) were administered daily to 27 children (3 males and 24 females, mean age 6.6 +/- 3 yr) for 7 days. Bacteriological results showed that at the end of followup (1 month) urine was sterile in 17 out of 24 children treated with fosfomycin trometamol (70.8%) and in 19 out of the 27 children treated with pipemidic acid (70.3%). One persistant infection and six reinfections were observed in the follow-up period in the fosfomycin group and 8 reinfections in the pipemidic acid group, usually in patients with urinary complications. No side effects were reported. The microbiological study of feces showed that neither of the drugs caused the emergence of resistant bacteria.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3652281

Source DB:  PubMed          Journal:  Chemioterapia        ISSN: 0392-906X


  4 in total

Review 1.  Fosfomycin trometamol: a review of its use as a single-dose oral treatment for patients with acute lower urinary tract infections and pregnant women with asymptomatic bacteriuria.

Authors:  Gillian M Keating
Journal:  Drugs       Date:  2013-11       Impact factor: 9.546

Review 2.  Fosfomycin.

Authors:  Matthew E Falagas; Evridiki K Vouloumanou; George Samonis; Konstantinos Z Vardakas
Journal:  Clin Microbiol Rev       Date:  2016-04       Impact factor: 26.132

Review 3.  Fosfomycin tromethamine. A review of its antibacterial activity, pharmacokinetic properties and therapeutic efficacy as a single-dose oral treatment for acute uncomplicated lower urinary tract infections.

Authors:  S S Patel; J A Balfour; H M Bryson
Journal:  Drugs       Date:  1997-04       Impact factor: 9.546

4.  Adverse Events Associated with Fosfomycin Use: Review of the Literature and Analyses of the FDA Adverse Event Reporting System Database.

Authors:  Dmitri Iarikov; Ronald Wassel; John Farley; Sumathi Nambiar
Journal:  Infect Dis Ther       Date:  2015-10-05
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.